211 related articles for article (PubMed ID: 18628415)
1. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma.
Jiang NY; Woda BA; Banner BF; Whalen GF; Dresser KA; Lu D
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1648-52. PubMed ID: 18628415
[TBL] [Abstract][Full Text] [Related]
2. Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.
Hang J; Hu H; Huang J; Han T; Zhuo M; Zhou Y; Wang L; Wang Y; Jiao F; Wang L
Oncotarget; 2016 May; 7(19):28207-17. PubMed ID: 27057636
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
4. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
5. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
6. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
8. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients.
Hu J; Hu H; Hang JJ; Yang HY; Wang ZY; Wang L; Chen DH; Wang LW
Oncotarget; 2016 Nov; 7(48):78557-78565. PubMed ID: 27713167
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.
Giaginis C; Tsourouflis G; Zizi-Serbetzoglou A; Kouraklis G; Chatzopoulou E; Dimakopoulou K; Theocharis SE
Pathol Oncol Res; 2010 Jun; 16(2):267-76. PubMed ID: 19949912
[TBL] [Abstract][Full Text] [Related]
11. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
12. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
13. Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance.
Wang L; Xiong L; Wu Z; Miao X; Liu Z; Li D; Zou Q; Yang Z
World J Surg Oncol; 2018 Jan; 16(1):11. PubMed ID: 29347944
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.
Yang L; Yang Z; Li D; Liu Z; Zou Q; Yuan Y; Xu H
Pathol Oncol Res; 2018 Oct; 24(4):899-906. PubMed ID: 28921449
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Yuan Y; Yang Z; Miao X; Li D; Liu Z; Zou Q
Tumour Biol; 2015 Dec; 36(12):9961-8. PubMed ID: 26178481
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
[TBL] [Abstract][Full Text] [Related]
18. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D; Wang J; Shi X; Yue B; Hao J
Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas.
Luo X; Yang Z; Liu X; Liu Z; Miao X; Li D; Zou Q; Yuan Y
Tumour Biol; 2017 May; 39(5):1010428317699129. PubMed ID: 28466777
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.
Cao D; Zhang Q; Wu LS; Salaria SN; Winter JW; Hruban RH; Goggins MS; Abbruzzese JL; Maitra A; Ho L
Mod Pathol; 2007 May; 20(5):570-8. PubMed ID: 17396143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]